drugset / Trial / NCT01283022

Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)

NCT01283022

Phase 2 Completed 24 enrolled Ferring Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine the pharmacokinetics (PK) of misoprostol acid for the MVI 200 in women requiring cervical ripening and induction of labor.

Timeline

Start
2011-05
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Misoprostol Other / unclassified 200 ug Other

Indications